Homepage Bottom Left
-
Health Canada approves Beqvez gene therapy for hemophilia B
Ottawa – January 3, 2024 – Health Canada has authorized Beqvez (fidanacogene elaparvovec), gene therapy for the treatment of hemophilia B. Beqvez is indicated for...
-
Gene Therapy Education Program – A CHS comprehensive information program
The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages...
-
Our continuing efforts to raise awareness about women and bleeding disorders
For almost 25 years, the CHS has played a key role in raising awareness about bleeding disorders that affect women. In 2012, to ensure the...
-
Health Canada approves Hemgenix gene therapy for hemophilia B
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
-
New shared decision-making tool (SDM) by the World Federation of Hemophilia
The World Federation of Hemophilia SDM Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between people with hemophilia A or...